We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Abbott Diagnostics

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
27 Oct 2020 - 31 Oct 2020
Virtual Venue
28 Oct 2020 - 30 Oct 2020
Virtual Venue

HPV, p16 Offers Different Prognostic Clues in Oropharyngeal Cancer

By LabMedica International staff writers
Posted on 07 Oct 2020
Print article
Image: Photomicrograph of histology of a poorly differentiated squamous cell carcinoma (SCC) that is p16 positive (Photo courtesy of Nephron).
Image: Photomicrograph of histology of a poorly differentiated squamous cell carcinoma (SCC) that is p16 positive (Photo courtesy of Nephron).
Human papillomavirus infection (HPV infection) is an infection caused by human papillomavirus (HPV), a DNA virus from the Papillomaviridae family. About 90% of HPV infections cause no symptoms and resolve spontaneously within two years.

Human papillomavirus-positive oropharyngeal cancer (HPV-positive OPC or HPV+OPC), is a squamous cell carcinoma of the throat caused by the human papillomavirus type 16 virus. Detection of a tumor suppressor protein, known as p16, is commonly used to diagnose an HPV associated OPC.

Oncologists at the Catalan Institute of Oncology (Barcelona, Spain) retrospectively analyze clinical features and outcomes in relation to p16 and HPV status in more than 7,700 individuals with oropharyngeal cancer enrolled in 13 cohorts from sites in nine European or North American countries. HPV and p16 were measured by immunohistochemistry (IHC) and the HPV DNA in situ hybridization (ISH) assay, respectively which can identify clusters of oropharyngeal cancers that appear to be at intermediate risk of recurrence or death compared to tumors that are p16-positive and HPV-positive and those lacking both markers.

IHC profiling is a sensitive approach for picking up p16, a surrogated marker for HPV, albeit with reduced specificity, since that host protein sometimes has enhanced expression even in the absence of HPV infection. On the other hand, the DNA ISH test is less sensitive, since it depends to some extent on the viral load, though it is also far more specific for finding risky HPV strains. Based on analyses done at a centralized site, the team classified 416 cases as p16-positive and HPV-negative, while 279 individuals with oropharyngeal cancer had p16-negative tumors testing positive for HPV by DNA ISH. The remaining patients included 3,598 with p16-negative and HPV-negative tumors and 3,409 cases classified as positive for both markers.

Nearly 90% of the p16-negative, HPV-negative cancers occurred in smokers, compared to a smoking rate of 62% in the patients with p16-positive, HPV-positive tumors. Notably, the cases showing discordant p16 and HPV marker status had smoking history in between these two groups. The team also saw a range of treatment interventions, including an uptick in surgeries and palliative care in the p16- and HPV-negative cases, followed by cases with HPV but not p16. When the investigators looked at overall survival in the biomarker-defined groups of stage III or IVa/b, locally advanced oropharyngeal cancer cases, they found that significantly more patients with p16- and HPV-positive tumors were alive after five years, whereas outcomes were more dire for the p16- and HPV-negative cases.

Miren Taberna, MD, a clinical oncologist and senior author of the study, said, “Using p16 staining alone, 11% of oropharyngeal cancer patients would be incorrectly classified as HPV-related, suggesting incorrect prognostic conclusions could be drawn from p16 testing alone, which would potentially place these patients in a de-escalation group inappropriately.” The study was presented at the European Society for Medical Oncology's Virtual Congress held in September 2020.

Related Links:
Catalan Institute of Oncology


Print article
BIOHIT  Healthcare OY

Channels

Molecular Diagnostics

view channel
Image: Photomicrograph of histology of a Ewing sarcoma in lung. The PAS stain highlights glycogen and the staining was negative with a PAS diastase stain (Photo courtesy of Nephron).

Comprehensive Molecular Profiling Matches Pediatric Patients to Therapies

A major challenge of using a comprehensive profiling approach for precision medicine is separating pathogenic from non-pathogenic molecular changes within a tumor. A program has been presented of the... Read more

Industry News

view channel
Image: Mindray Hematology Solution Helps High-Volume Lab Run 2,820,000 CBC Tests Annually (Photo courtesy of Mindray)

Mindray Hematology Solution Helps High-Volume Lab Run 2,820,000 CBC Tests Annually

High-volume laboratories face several challenges, including high instrument failure rate, errors due to several manual steps, low efficiency and long TAT, and heavier workload for the lab staff.... Read more
Copyright © 2000-2020 Globetech Media. All rights reserved.